2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity

Comparative Analysis of Methods for Detecting Isocitrate Dehydrogenase 1 and 2 Mutations and Their Metabolic Consequence, 2-Hydroxyglutarate, in Different Neoplasms

(2017) Shahab Babakoohi et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY

IDH mutations in cancer and progress toward development of targeted therapeutics

(2016) L. Dang et al.   ANNALS OF ONCOLOGY

Combenefit: an interactive platform for the analysis and visualization of drug combinations

(2016) Giovanni Y. Di Veroli et al.   BIOINFORMATICS

Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer

(2016) Huai-Qiang Ju et al.   CANCER LETTERS

Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer

(2016) O. Clark et al.   CLINICAL CANCER RESEARCH

Characterization of Cardiac Glycoside Natural Products as Potent Inhibitors of DNA Double-Strand Break Repair by a Whole-Cell Double Immunofluorescence Assay

(2016) Yulia V. Surovtseva et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

miR-155 Overexpression Promotes Genomic Instability by Reducing High-fidelity Polymerase Delta Expression and Activating Error-Prone DSB Repair

(2016) J. R. Czochor et al.   MOLECULAR CANCER RESEARCH

Distinct binding of BRCA2 BRC repeats to RAD51 generates differential DNA damage sensitivity

(2016) Gouri Chatterjee et al.   NUCLEIC ACIDS RESEARCH

Drugging DNA repair

(2016) Stephen P. Jackson et al.   SCIENCE

KDM4A Coactivates E2F1 to Regulate the PDK-Dependent Metabolic Switch between Mitochondrial Oxidation and Glycolysis

(2016) Ling-Yu Wang et al.   Cell Reports

Synthetic Lethal Vulnerabilities of Cancer

(2015) Ferran Fece de la Cruz et al.   Annual Review of Pharmacology and Toxicology

Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion

(2015) Kensuke Tateishi et al.   CANCER CELL

Noninvasive Quantification of 2-Hydroxyglutarate in Human Gliomas with IDH1 and IDH2 Mutations

(2015) U. E. Emir et al.   CANCER RESEARCH

Hypoxia Induces Production of L-2-Hydroxyglutarate

(2015) Andrew M. Intlekofer et al.   Cell Metabolism

Hypoxia-Mediated Increases in l -2-hydroxyglutarate Coordinate the Metabolic Response to Reductive Stress

(2015) William M. Oldham et al.   Cell Metabolism

Drugging ATR: progress in the development of specific inhibitors for the treatment of cancer

(2015) Kevin M Foote et al.   Future Medicinal Chemistry

Reductive carboxylation and 2-hydroxyglutarate formation by wild-type IDH2 in breast carcinoma cells

(2015) Katarína Smolková et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Targeting cancer with kinase inhibitors

(2015) Stefan Gross et al.   JOURNAL OF CLINICAL INVESTIGATION

Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial

(2015) Amit M Oza et al.   LANCET ONCOLOGY

YU238259 Is a Novel Inhibitor of Homology-Dependent DNA Repair That Exhibits Synthetic Lethality and Radiosensitization in Repair-Deficient Tumors

(2015) G. C. Stachelek et al.   MOLECULAR CANCER RESEARCH

Integrated genomic characterization of IDH1-mutant glioma malignant progression

(2015) Hanwen Bai et al.   NATURE GENETICS

Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia

(2015) Steven M Chan et al.   NATURE MEDICINE

Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells

(2015) Luyuan Li et al.   PLoS One

The Contribution of Ketone Bodies to Basal and Activity-Dependent Neuronal Oxidation in Vivo

(2014) Golam MI Chowdhury et al.   JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM

Benefit From Procarbazine, Lomustine, and Vincristine in Oligodendroglial Tumors Is Associated With Mutation ofIDH

(2014) J. Gregory Cairncross et al.   JOURNAL OF CLINICAL ONCOLOGY

KDM4B as a Target for Prostate Cancer: Structural Analysis and Selective Inhibition by a Novel Inhibitor

(2014) Chia-Han Chu et al.   JOURNAL OF MEDICINAL CHEMISTRY

Phase I/Ib Study of Olaparib and Carboplatin in BRCA1 or BRCA2 Mutation-Associated Breast or Ovarian Cancer With Biomarker Analyses

(2014) Jung-Min Lee et al.   JNCI-Journal of the National Cancer Institute

Hypoxic Stress Facilitates Acute Activation and Chronic Downregulation of Fanconi Anemia Proteins

(2014) Susan E. Scanlon et al.   MOLECULAR CANCER RESEARCH

Identification of Novel Radiosensitizers in a High-Throughput, Cell-Based Screen for DSB Repair Inhibitors

(2014) A. G. Goglia et al.   MOLECULAR CANCER THERAPEUTICS

Tracing Compartmentalized NADPH Metabolism in the Cytosol and Mitochondria of Mammalian Cells

(2014) Caroline A. Lewis et al.   MOLECULAR CELL

A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a Pediatric Brain Tumor Consortium report†

(2014) Jack M. Su et al.   NEURO-ONCOLOGY

The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone

(2014) Remco J. Molenaar et al.   NEURO-ONCOLOGY

L-2-Hydroxyglutarate: An Epigenetic Modifier and Putative Oncometabolite in Renal Cancer

(2014) E.-H. Shim et al.   Cancer Discovery

OpenComet: An automated tool for comet assay image analysis

(2014) Benjamin M. Gyori et al.   Redox Biology

What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer

(2013) J.-A. Losman et al.   GENES & DEVELOPMENT

Kdm4b Histone Demethylase Is a DNA Damage Response Protein and Confers a Survival Advantage following γ-Irradiation

(2013) Leah C. Young et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis

(2013) Atsushi Terunuma et al.   JOURNAL OF CLINICAL INVESTIGATION

Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas

(2013) Yuchen Jiao et al.   NATURE GENETICS

Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry

(2013) A. N. Tran et al.   NEURO-ONCOLOGY

Development of an assay to measure mutagenic non-homologous end-joining repair activity in mammalian cells

(2013) Ranjit S. Bindra et al.   NUCLEIC ACIDS RESEARCH

An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells

(2013) D. Rohle et al.   SCIENCE

Survival of the Replication Checkpoint Deficient Cells Requires MUS81-RAD52 Function

(2013) Ivana Murfuni et al.   PLoS Genetics

Enzymatic assay for quantitative analysis of (d)-2-hydroxyglutarate

(2012) Jörg Balss et al.   ACTA NEUROPATHOLOGICA

RNF8- and RNF168-dependent degradation of KDM4A/JMJD2A triggers 53BP1 recruitment to DNA damage sites

(2012) Frédérick A Mallette et al.   EMBO JOURNAL

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

(2012) Sevin Turcan et al.   NATURE

Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma

(2012) Michael Krauthammer et al.   NATURE GENETICS

Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas

(2012) P Wang et al.   ONCOGENE

Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases

(2011) Wei Xu et al.   CANCER CELL

IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours

(2011) M Fernanda Amary et al.   JOURNAL OF PATHOLOGY

Hypoxia-Induced Epigenetic Regulation and Silencing of the BRCA1 Promoter

(2011) Y. Lu et al.   MOLECULAR AND CELLULAR BIOLOGY

Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells

(2011) A. G. Patel et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The prognostic IDH1 R132 mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma

(2010) Fonnet E. Bleeker et al.   ACTA NEUROPATHOLOGICA

Tumor Growth Inhibition by Olaparib in BRCA2 Germline-Mutated Patient-Derived Ovarian Cancer Tissue Xenografts

(2010) U. Kortmann et al.   CLINICAL CANCER RESEARCH

NAD+ Depletion Is Necessary and Sufficient forPoly(ADP-Ribose) Polymerase-1-Mediated Neuronal Death

(2010) C. C. Alano et al.   JOURNAL OF NEUROSCIENCE

Erratum: Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

(2010) Lenny Dang et al.   NATURE

Plasma and cerebrospinal fluid pharmacokinetics of ABT-888 after oral administration in non-human primates

(2009) Jodi A. Muscal et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Functional Restoration of BRCA2 Protein by Secondary BRCA2 Mutations in BRCA2-Mutated Ovarian Carcinoma

(2009) W. Sakai et al.   CANCER RESEARCH

Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome

(2009) Elaine R. Mardis et al.   NEW ENGLAND JOURNAL OF MEDICINE

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Catalytic Subunit of DNA-Dependent Protein Kinase Regulates Proliferation, Telomere Length, and Genomic Stability in Human Somatic Cells

(2008) B. L. Ruis et al.   MOLECULAR AND CELLULAR BIOLOGY

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

(2008) D. W. Parsons et al.   SCIENCE